GENE ONLINE|News &
Opinion
Blog

2018-10-11| Asia-PacificPolicy

Live Report – 2018 BioJapan: Witness Japan’s biotechnology industry development policy and the innovation of pharmaceutical industry

by GeneOnline
Share To

2018 BioJapan was launched on October 10th at Pacifico Yokohama National Convention Hall. GeneOnline listed some of the highlights shared by two key opinion leaders in medicine.

Concentrate on the development of biotechnology in order to solve the issues on society.

Mazakazu Tokura, the president of SUMITOMO CHEMICAL , also a member of Council for Science, Technology and Innovation (CSTI), mentioned that Japanese government has outlined “Society 5.0” project in “Japan Revitalization Strategy”, in order to integrate the relevant units and implement the effective resource allocation and structural reform.

Mazakazu Tokura, the president of SUMITOMO CHEMICAL , also a member of Council for Science, Technology and Innovation (CSTI)
Mazakazu Tokura, the president of SUMITOMO CHEMICAL , also a member of Council for Science, Technology and Innovation (CSTI)

Regarding to this, Japanese government’s appeal is to let the policy and technology development become closer, more organized and flexible, and commit to expanding the market and accelerating the development of computer science and biotechnology.

The technology integration is real data and domain technology for biotechnology, which combines big data in various fields with cutting edge technologies such as genetic technology, AIoT, bioinformatics, etc. As well as connects to the country that has sound system on biomedical, such as the United States, United Kingdom, Germany, etc., in order to become the well-known country in global biotechnology industry.

The future of drug development and innovation

George Nakayama, president of Japan Pharmaceutical Manufacturers Association (JPMA), introduced that JPMA consists of 71 research-based pharmaceuticals in Japan and is a research-oriented voluntary organization.

George Nakayama, president of Japan Pharmaceutical Manufacturers Association (JPMA)
George Nakayama, president of Japan Pharmaceutical Manufacturers Association (JPMA)

He mentioned that Japan should work hard in three directions to catch up with the United States. To begin with, the establishment of the infrastructure, including the establishment of a health care database, such as genome and clinical diagnostic information, and the construction of ID facilities. Then, in order to provide sufficient funds for basic scientific research, the government and industry should cooperate to create profits. Finally, the government should establish an ecosystem without borders, especially establish a close relationship with the United States actively.

“Stay tuned to GeneOnline for more special articles on BioJapan 2018”

medtex最新-e1538653867506

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Connecting Biotech Ecosystems: Success of Los Angeles Event Sets Stage for APAC-US Collaboration
2024-04-10
R&D
Innovating Prostate Cancer Care: SYNC-T, Proteogenomics, and Culturally Tailored Education at AACR 2024
2024-04-10
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
LATEST
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top